Arcadia Biosciences financials
$0.2807−8.86%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.9M | $5.0M | $4.5M | $7.4M | $6.8M | $8.0M | $1.2M | $1.5M | $4.0M | $3.2M |
| Gross profit | $1.8M | $2.1M | $2.3M | $1.3M | -$1.9M | $2.8M | $284.0K | $803.0K | $3.7M | $2.3M |
| Gross margin | 36.2% | 41.3% | 51.2% | 17.8% | −28.4% | 35.3% | 24.3% | 54.8% | 93.0% | 71.9% |
| Operating income | -$3.3M | -$7.6M | -$6.1M | -$15.5M | -$35.0M | -$21.6M | -$19.4M | -$16.9M | -$14.3M | -$18.6M |
| Net income | -$2.3M | -$4.3M | -$14.0M | -$15.4M | -$14.7M | -$4.7M | -$28.8M | -$13.5M | -$15.7M | -$19.6M |
| Net margin | −48.1% | −85.6% | −313.9% | −207.3% | −216.2% | −57.9% | −2464.1% | −920.8% | −390.1% | −615.6% |
| Diluted EPS | $-1.71 | $-3.17 | $-11.29 | $-25.65 | $-27.56 | $-18.80 | $-181.20 | $-143.20 | $-291.20 | $-354.00 |
| EBITDA | -$3.2M | -$7.5M | -$5.7M | -$14.7M | -$26.4M | -$19.9M | -$19.5M | -$16.7M | -$14.0M | -$18.3M |
| Operating cash flow | -$4.7M | -$9.6M | -$15.3M | -$14.0M | -$25.9M | -$30.2M | -$17.2M | -$13.6M | -$14.0M | -$17.1M |
| Free cash flow | -$4.7M | -$9.6M | -$15.3M | -$14.0M | -$26.9M | -$32.6M | -$18.7M | -$13.9M | -$14.0M | -$17.3M |
| Diluted shares | 1.4M | 1.4M | 1.2M | 0.6M | 0.5M | 0.2M | 0.2M | 0.1M | 0.1M | 0.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $259.0K | $4.2M | $6.5M | $20.6M | $28.7M | $14.0M |
| Short-term investments | $4.3M | $0.00 | $5.1M | $0.00 | — | $11.6M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $3.2M |
| Total assets | $6.5M | $13.5M | $19.7M | $28.9M | $43.9M | $47.3M |
| Total liabilities | $2.4M | $7.3M | $7.0M | $8.0M | $12.7M | $16.1M |
| Shareholders' equity | $4.1M | $6.2M | $12.7M | $20.9M | $31.2M | $31.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology